Treats metastatic colorectal cancer. ANDA 207548, held by Amneal. Levoleucovorin Calcium.
As of Nov 16, 2026, ANDA 207548 (Levoleucovorin Calcium), held by Amneal, was first approved by FDA on Sep 8, 2017, with 2 approved supplements and 0 published complete response letters.
Levoleucovorin injection is indicated for: rescue after high-dose methotrexate therapy in adult and pediatric patients with osteosarcoma. diminishing the toxicity associated with overdosage of folic acid antagonists or impaired methotrexate elimination in adult and pediatric patients. the treatment of adults with metastatic colorectal cancer in combination with fluorouracil. Limitations of Use Levoleucovorin injection is not indicated for pernicious anemia and megaloblastic anemia secondary to the lack of vitamin B 12, because of the risk of progression of neurologic manifestations despite hematologic remission.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 8, 2017 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Levoleucovorin CalciumEQ 175MG BASE/17.5ML (EQ 10MG BASE/ML) · solution;intravenous | Levoleucovorin Calcium | Discontinued |
| Dec 14, 2022 | Supplement 1Labeling · Standard review | Approved | None posted |
| Dec 14, 2022 | Supplement 5Labeling · Standard review | Approved | None posted |
| Sep 8, 2017 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters